(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
NAFFIC and Aware to Launch First China-Europe Digital Product Passport - 2Exploring ways to reduce the impact of space junk on Earth
- 3German official report: Teen social media ban faces legal hurdles
- 4Vote in favor of the pasta that makes good dieting pleasant!
- 5Osteoporosis, the silent disease, can shorten your life − here’s how to prevent fractures and keep bones healthy
- How to sound like an astronaut as you follow the first human moon mission in more than half a century
- Best Pizza Beating: What's Your #1?
- Tesla plans to expand production at German car plant
- Addiction-stricken community struggles to keep a syringe program going after Trump's order
- The Response to Self-improvement: Embracing a Development Outlook
- Former biotech CEO sued over COVID vaccine alleged insider trading
- Toddler diagnosed with cancer makes remarkable recovery after aggressive treatment
- Manual for Picking the Ideal Wine Matching
- Washington resident contracts bird flu, first human case in U.S. since February
